Editas Medicine (EDIT) Common Equity (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Common Equity data on file, last reported at $27.3 million in Q4 2025.

• On a quarterly basis, Common Equity fell 79.68% year-over-year to $27.3 million in Q4 2025; TTM through Dec 2025 was $27.3 million, a 79.68% decrease from a year earlier, with the FY2025 full-year figure at $27.3 million, down 79.68% from the prior year.
• Common Equity for Q4 2025 stood at $27.3 million, up from $13.5 million in the prior quarter.
• Over the last five years, Common Equity for EDIT reached as high as $638.0 million in Q1 2021 and fell as low as $13.5 million in Q3 2025.
• Historically, Common Equity has averaged $326.6 million across 5 years, with a median of $354.8 million in 2023.
• Across the five-year window, Common Equity surged 171.99% in 2021 and slumped 92.34% in 2025, its largest moves.
• Year by year, Common Equity stood at $553.6 million in 2021, then tumbled by 34.85% to $360.7 million in 2022, then decreased by 3.21% to $349.1 million in 2023, then sank by 61.54% to $134.3 million in 2024, then plunged by 79.68% to $27.3 million in 2025.
• Per Business Quant data, the three most recent Common Equity figures were $27.3 million in Q4 2025, $13.5 million in Q3 2025, and $19.2 million in Q2 2025.